



Medicine: avatrombopag (brand name: Doptelet®)

Swedish Orphan Biovitrum Ltd (UK)

The Scottish Medicines Consortium (SMC) has assessed avatrombopag for the treatment of severe thrombocytopenia (low level of platelets in the blood) in adults with chronic liver disease who are scheduled to undergo an invasive surgical procedure. This document summarises the SMC decision and what it means for patients.

What has SMC said?

After careful consideration, SMC has accepted avatrombopag for the treatment of severe thrombocytopenia in adults with chronic liver disease as described above.

What does SMC's decision mean for patients?

If your healthcare professional thinks that avatrombopag for use as described above is the right medicine for you, you should be able to have the treatment on the NHS in Scotland.



What is avatrombopag used for?

Avatrombopag is used to prevent excessive bleeding in adults with thrombocytopenia that is caused by chronic liver disease. Patients with thrombocytopenia have a reduced number of platelets, which are a component of blood that help it to clot. Avatrombopag is a treatment for patients who have severe thrombocytopenia due to chronic liver disease and who are having an invasive procedure (e.g. a surgical or diagnostic procedure that involves cutting the skin).

How does avatrombopag work?

Platelets are made in the bone marrow. Avatrombopag stimulates the bone marrow to produce more platelets, helping to increase the number of platelets in the bloodstream. This helps the blood to clot more easily.

How does SMC make its decision?

SMC carefully considers every new medicine to make sure it benefits patients and is considered to be an acceptable use of the limited resources in NHSScotland.

To do this SMC considers the following:

- Evidence from the company about how well the medicine works compared with current treatments available in Scotland, in relation to how much they will cost to buy and administer.
- The potential impact of the medicine on patients and carers.
- Advice from healthcare professionals about any benefits of the new medicine compared to current treatment, along with how the new medicine is likely to be used.

When SMC assesses a medicine it takes account of the needs of all patients in NHS Scotland, not just those who may be treated with the medicine under consideration.

You can find more detailed information about the SMC assessment of avatrombopag by looking at the SMC Detailed Advice Document (SMC2296).

More information

The organisations below can provide more information and support for people with liver disease and their families. SMC is not responsible for the content of any information provided by external organisations.

The British Liver Trust



<http://www.britishlivertrust.org.uk>



0800 652 7330

The PBC Foundation



<https://www.pbcfoundation.org.uk>



0131 556 6811

You can find out more about avatrombopag (Doptelet®) in the European public assessment report (EPAR) summary for the public by searching for the medicine name on the European Medicines Agency (EMA) website.



<http://www.ema.europa.eu>